Journal: bioRxiv
Article Title: Acquired resistance to the PRMT5 inhibitor confers collateral sensitivity to MEK inhibition in MTAP-null non-small cell lung cancer
doi: 10.64898/2026.04.16.719008
Figure Lengend Snippet: Assessment of MTAP status and PRMT5 inhibition in MTAP-isogenic cells. (A) Immunoblot analysis of MTAP and PRMT5 protein levels across a panel of NSCLC cell lines. (B) Immunoblot validation of MTAP expression in MTAP-isogenic murine and human cell lines. (C) Immunoblot analysis of SDMA levels in the A375 MTAP-isogenic cell pair following treatment with increasing concentrations of EPZ015666 or MRTX1719.
Article Snippet: Human NSCLC cell lines H1299 (#CRL-5803, RRID: CVCL_0060, sex: male), H1975 (#CRL-5908, RRID: CVCL_1511, sex: female), A549 (#CCL-185, RRID: CVCL_0023, sex: male), H838 (#CRL-5844, RRID: CVCL_1594, sex: male), H1437 (#CRL-5872, RRID: CVCL_1472, sex: male), and H2126 (#CCL-256, RRID: CVCL_1532, sex: male); the human SCLC cell line H2171 (#CRL-5929, RRID: CVCL_1536, sex: male); human colorectal cancer cell lines RKO (#CRL-2577, RRID: CVCL_0504, sex: unspecified) and DLD1 (#CCL-221, RRID: CVCL_0248, sex: male); the human melanoma cell line A375 (#CRL-1619, RRID: CVCL_0132, sex: female); and the murine melanoma cancer cell lines B16-F10 (#CRL-6475, RRID: CVCL_0159, sex: male) were obtained from the American Type Culture Collection (ATCC).
Techniques: Inhibition, Western Blot, Biomarker Discovery, Expressing